Better Therapeutics, Inc. Common Stock
BTTX
BTTX was delisted on the 15th of March, 2024.
14 hedge funds and large institutions have $2.77M invested in Better Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 5 closing their positions.
1,580% more call options, than puts
Call options by funds: $420K | Put options by funds: $25K
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
0% more funds holding
Funds holding: 14 → 14 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
61% less capital invested
Capital invested by funds: $7.16M → $2.77M (-$4.39M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$157K |
| 2 |
BlackRock
New York
|
+$127K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$114K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$82.2K |
| 5 |
State Street
Boston,
Massachusetts
|
+$75.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.74M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$1.18M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$540K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$371K |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$247K |
BTTX Hedge Fund Activity: Q2 2022 in Review
14 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Better Therapeutics, Inc. Common Stock (BTTX) for Q2 2022, worth a combined $2.77M — down 61% from $7.16M a quarter earlier.
Fund positioning in BTTX was balanced in Q2 2022: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $157K. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $1.74M sold.
- 14 institutional investors held Better Therapeutics, Inc. Common Stock (BTTX) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $2.77M of Better Therapeutics, Inc. Common Stock stock for Q2 2022, down 61% quarter-over-quarter.
- 5 funds opened new Better Therapeutics, Inc. Common Stock positions in Q2 2022 and 5 closed out, a net change of 0 holders.
- The largest Better Therapeutics, Inc. Common Stock buyer in Q2 2022 was Morgan Stanley, an estimated $157K added.
- The largest Better Therapeutics, Inc. Common Stock seller in Q2 2022 was Sectoral Asset Management, an estimated $1.74M sold.
Based on aggregated 13F filings for Q2 2022.